Progressive cognitive decline in physiological aging
Conditions
Interventions
Product Name: Levobeta®
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa, Carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100 (Levodopa)-25 (Carb
Sponsors
Kognitive Neurologie, Institut für Medizin, Forschungszentrum Jülich
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Healthy subjects age range 18-75 years -Right-handed -fluent in German language -capable of informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: -neurological or psychiatric disease -any severe medical condition -asthma bronchiale, suspicion of melanoma, gangrene, coronary heart disease, mechanical obstipation of bowels or urinary pathways, glaucoma, hyperthyreosis, cardial arrhythmia, diarrhea -known allergic reactions to Sulfite, Glycopyrroniumbromid, Levodopa/Carbidopa, Physostigminsalicylate -regular intake of centrally active pharmacological agents -intake of MAO-A-inhibitors or other cholinesterase-inhibitors -pregnancy or lactation -incorporated ferromagnetic objects (e.g. pace-maker, intrauterine-devices, endoprothesis of the joints, tattoos, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Investigation of neurochemical modulation of higher cognitive functions in different age-groups (young versus elderly): investigation of behavioural and neural alterations of executive functions following dopaminergic stimulation and of memory functions following cholinergic stimulation.;Secondary Objective: Understanding neurochemical mechanisms of cognitive aging, for optimising pharmocointervention in the neurorehabilitation of higher cognitive functions (e.g. in age-related cognitive decline and in conditions with dysexecutive syndromes or impaired memory functions such as dementia, Parkinson’s disease and stroke);Primary end point(s): BOLD-effect | — |
Countries
Germany
Outcome results
None listed